163 related articles for article (PubMed ID: 32711101)
1. The transcription factor CBFB mutations indicate an improved survival in HR+/HER2- breast cancer.
Guo L; Chen B; Zhang G; Wang Y; Cao L; Ren C; Wen L; Lin J; Wei G; Liao N
Gene; 2020 Oct; 759():144970. PubMed ID: 32711101
[TBL] [Abstract][Full Text] [Related]
2. Association between histone lysine methyltransferase KMT2C mutation and clinicopathological factors in breast cancer.
Chen X; Zhang G; Chen B; Wang Y; Guo L; Cao L; Ren C; Wen L; Liao N
Biomed Pharmacother; 2019 Aug; 116():108997. PubMed ID: 31146111
[TBL] [Abstract][Full Text] [Related]
3. Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA.
Li X; Chen X; Wen L; Wang Y; Chen B; Xue Y; Guo L; Liao N
Thorac Cancer; 2020 Jul; 11(7):1861-1868. PubMed ID: 32412177
[TBL] [Abstract][Full Text] [Related]
4. Characterization of AKT Somatic Mutations in Chinese Breast Cancer Patients.
Wen L; Zhang G; Ren C; Li X; Mok H; Jia M; Wang Y; Chen B; Li K; Cao L; Li C; Xiao W; Lai J; Lin J; Wei G; Li Y; Zhang Y; Chen X; Liao N
Cancer Manag Res; 2021; 13():3055-3065. PubMed ID: 33854375
[TBL] [Abstract][Full Text] [Related]
5. Spectrum of
Li C; Zhang G; Wang Y; Chen B; Li K; Cao L; Ren C; Wen L; Jia M; Mok H; Lai J; Xiao W; Li X; Liao N
Oncol Lett; 2022 Feb; 23(2):68. PubMed ID: 35069877
[TBL] [Abstract][Full Text] [Related]
6. Distinct clinicopathological characteristics, genomic alteration and prognosis in breast cancer with concurrent TP53 mutation and MYC amplification.
Lin X; Lin X; Guo L; Wang Y; Zhang G
Thorac Cancer; 2022 Dec; 13(24):3441-3450. PubMed ID: 36305094
[TBL] [Abstract][Full Text] [Related]
7. Integrated analysis of cell cycle-related genes in HR+/HER2- breast cancer.
Lai J; Chen B; Li Y; Lin X; Li M; Liu J; Liao N
Breast Cancer; 2022 Jan; 29(1):121-130. PubMed ID: 34449047
[TBL] [Abstract][Full Text] [Related]
8. Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts.
Zhang G; Wang Y; Chen B; Guo L; Cao L; Ren C; Wen L; Li K; Jia M; Li C; Mok H; Chen X; Wei G; Lin J; Zhang Z; Hou T; Han-Zhang H; Liu C; Liu H; Liu J; Balch CM; Meric-Bernstam F; Liao N
Ann Transl Med; 2019 Apr; 7(8):179. PubMed ID: 31168460
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of
Cao L; Ren C; Zhang G; Li X; Chen B; Li K; Li C; Mok H; Wang Y; Wen L; Jia M; Wei G; Lin J; Liao N
DNA Cell Biol; 2022 May; 41(5):521-538. PubMed ID: 35475703
[No Abstract] [Full Text] [Related]
10. High expression of the vacuole membrane protein 1 (VMP1) is a potential marker of poor prognosis in HER2 positive breast cancer.
Amirfallah A; Arason A; Einarsson H; Gudmundsdottir ET; Freysteinsdottir ES; Olafsdottir KA; Johannsson OT; Agnarsson BA; Barkardottir RB; Reynisdottir I
PLoS One; 2019; 14(8):e0221413. PubMed ID: 31442252
[TBL] [Abstract][Full Text] [Related]
11. GATA3 mutations define a unique subtype of luminal-like breast cancer with improved survival.
Jiang YZ; Yu KD; Zuo WJ; Peng WT; Shao ZM
Cancer; 2014 May; 120(9):1329-37. PubMed ID: 24477928
[TBL] [Abstract][Full Text] [Related]
12. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.
Park YH; Shin HT; Jung HH; Choi YL; Ahn T; Park K; Lee A; Do IG; Kim JY; Ahn JS; Park WY; Im YH
Oncotarget; 2015 Oct; 6(31):32027-38. PubMed ID: 26397225
[TBL] [Abstract][Full Text] [Related]
13. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
Liang X; Vacher S; Boulai A; Bernard V; Baulande S; Bohec M; Bièche I; Lerebours F; Callens C
Breast Cancer Res; 2018 Aug; 20(1):88. PubMed ID: 30086764
[TBL] [Abstract][Full Text] [Related]
14. Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.
Lefebvre C; Bachelot T; Filleron T; Pedrero M; Campone M; Soria JC; Massard C; Lévy C; Arnedos M; Lacroix-Triki M; Garrabey J; Boursin Y; Deloger M; Fu Y; Commo F; Scott V; Lacroix L; Dieci MV; Kamal M; Diéras V; Gonçalves A; Ferrerro JM; Romieu G; Vanlemmens L; Mouret Reynier MA; Théry JC; Le Du F; Guiu S; Dalenc F; Clapisson G; Bonnefoi H; Jimenez M; Le Tourneau C; André F
PLoS Med; 2016 Dec; 13(12):e1002201. PubMed ID: 28027327
[TBL] [Abstract][Full Text] [Related]
15. CBFB cooperates with p53 to maintain TAp73 expression and suppress breast cancer.
Malik N; Yan H; Yang HH; Ayaz G; DuBois W; Tseng YC; Kim YI; Jiang S; Liu C; Lee M; Huang J
PLoS Genet; 2021 May; 17(5):e1009553. PubMed ID: 33945523
[TBL] [Abstract][Full Text] [Related]
16. MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer.
Han J; Choi YL; Kim H; Choi JY; Lee SK; Lee JE; Choi JS; Park S; Choi JS; Kim YD; Nam SJ; Nam BH; Kwon MJ; Shin YK
Breast Cancer Res Treat; 2017 Jul; 164(1):41-56. PubMed ID: 28409241
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of genomic profile in patients with HER2-positive breast cancer.
Chen B; Zhang G; Wei G; Wang Y; Guo L; Lin J; Li K; Mok H; Cao L; Ren C; Wen L; Jia M; Li C; Hou T; Han-Zhang H; Liu J; Balch CM; Liao N
Endocr Relat Cancer; 2020 Mar; 27(3):153-162. PubMed ID: 31905165
[TBL] [Abstract][Full Text] [Related]
18. HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis.
Tan RSYC; Ong WS; Lee KH; Lim AH; Park S; Park YH; Lin CH; Lu YS; Ono M; Ueno T; Naito Y; Onishi T; Lim GH; Tan SM; Lee HB; Ryu HS; Han W; Tan VKM; Wong FY; Im SA; Tan PH; Chan JY; Yap YS
BMC Med; 2022 Mar; 20(1):105. PubMed ID: 35296300
[TBL] [Abstract][Full Text] [Related]
19. HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features.
Ding Q; Chen H; Lim B; Damodaran S; Chen W; Tripathy D; Piha-Paul S; Luthra R; Meric-Bernstam F; Sahin AA
Hum Pathol; 2019 Oct; 92():32-38. PubMed ID: 31351155
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer.
Kariri YA; Joseph C; Kurozumi S; Toss MS; Alsaleem M; Raafat S; Mongan NP; Aleskandarany MA; Green AR; Rakha EA
Breast Cancer Res Treat; 2020 Jan; 179(2):349-357. PubMed ID: 31679074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
